+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Aristada"

From
Antipsychotic Drugs: Technologies and Global Markets - Product Thumbnail Image

Antipsychotic Drugs: Technologies and Global Markets

  • Report
  • September 2018
  • 174 Pages
  • Global
From
Schizophrenia Disease Coverage to 2024 - Product Thumbnail Image

Schizophrenia Disease Coverage to 2024

  • Report
  • July 2019
  • 498 Pages
  • Global
Drug Overview: Aristada - Product Thumbnail Image

Drug Overview: Aristada

  • Report
  • March 2018
  • 16 Pages
  • Global
From
Disease Analysis: Schizophrenia - Product Thumbnail Image

Disease Analysis: Schizophrenia

  • Report
  • March 2021
  • 101 Pages
  • Global
Aristada - API Insight, 2022 - Product Thumbnail Image

Aristada - API Insight, 2022

  • Drug Pipelines
  • January 2022
  • 30 Pages
  • Global
From
Aristada- Drug Insight, 2019 - Product Thumbnail Image

Aristada- Drug Insight, 2019

  • Report
  • January 2019
  • 35 Pages
  • Global
From
  • 7 Results (Page 1 of 1)
Loading Indicator

Aristada is a brand of long-acting injectable antipsychotic medications used to treat schizophrenia. It is a once-monthly injection that helps to reduce symptoms of schizophrenia, such as hallucinations, delusions, and disorganized thinking. Aristada is a combination of aripiprazole and paliperidone palmitate, two drugs that work together to reduce symptoms of schizophrenia. Aristada is designed to provide a steady, consistent level of medication in the body over a longer period of time than other antipsychotic medications. This helps to reduce the risk of relapse and improve overall outcomes for people with schizophrenia. Companies in the Aristada market include Alkermes, Otsuka Pharmaceuticals, and Lundbeck. Show Less Read more